

an Mr. Stuart Tipple

Marburg/L., den 21.7.1983 Blatt - 2 -

Our company records evidence that bottles of antiserum against haemoglobin F from batch number 2456 were supplied to the Australian distributor from April 1975 to September 1982.

Antiserum against haemoglobin F is not listed in our commercial catalogue since it is produced as a special laboratory product which does not have defined uses. Therefore, the application and suitability for use of the antiserum is the responsibility of the user. Behringwerke does not guarantee that the anti-haemoglobin F antiserum will react only with haemoglobin F in all test conditions.

Following enquiries received from Professor B. Boettcher a series of tests on antiserum to haemoglobin F was conducted, mainly in the period of March and April, 1983. The repeated results of the tests demonstrate the following conclusions:

Firstly, the antiserum has been adjusted to be specific when reacted against plasma proteins in the agar gel double diffusion (Ouchterlony) technique and immunoelectrophoresis.

Secondly, the antiserum might react with other proteins e.g. with cell proteins that have entered the plasma.

Thirdly, non-specific immune reactions can be observed under certain conditions due to denaturation of haemoglobin A in adult blood or due to alteration of the relative concentrations of antigen and antibody.


Fourthly, the antiserum against haemoglobin F of Behringwerke, therefore, is not suitable on its own for the identification of foetal/infant blood and adult blood.


an Mr. Stuart Tipple

Marburg/L., den 21.7.1983 Blatt - 3 -

This statement is made by Behringwerke AG by duly authorised officers namely Dr. rer. nat. Klaus Störiko, General Manager for Production of Diagnostics and Dr. rer. nat. Siegfried Baudner, Production Manager and Head of the Plasma Protein Research Laboratory.

BEHRINGWERKE
Aktiengesellschaft


Dr. Störiko


Dr. Baudner